Sabinsa, an ingredients supplier in the nutraceutical and cosmeceutical spaces, was recently granted a new patent in Mexico for its Boswellia serrata extract, Boswellin PS.
 
The patent, MX328842, is for a synergistic composition containing boswellic acids and polysaccharides obtained from the Boswellia species, which has been evidenced to downregulate a number of pro-inflammatory markers, including PGE2, for example, which is associated with the inflammatory processes of multiple diseases.
 
In addition to its bioactive boswellic acids, the ingredient contains a substantial amount of polysol, which has also been shown to contribute to the mechanisms by which the ingredient mitigates the inflammatory response. Lastly, the Boswellia extract contains AKBA, a triterpene that some researchers theorize may induct apoptosis, an essential process in normal animal development and in the renewal of cell populations in the human body, Sabinsa reports.
 
“Inflammation is an underlying cause of many health conditions throughout the world,” Dr. Muhammed Majeed, founder and chairman of Sabinsa, said. “By applying modern research to ancient Ayurvedic knowledge, Sabinsa has been able to provide natural solutions, including the Boswellin PS ingredient, to this common condition.”
 
Similar patents have been granted to the ingredient in Australia, Canada, Taiwan, and other countries in Europe and Asia. Boswellin PS is shown to be significantly more water-soluble than its Boswellin counterpart.